Key Highlights
- Revenue was USD 17.23 million against an estimate of USD 16.32 million.
- Loss per share was USD 2.89 against an estimate of a USD 2.39 loss.
- Net loss was USD 53.3 million, against USD 32.0 million a year earlier.
- Cash and cash equivalents were approximately USD 162.8 million.
Tonix Pharmaceuticals (NASDAQ:TNXP) reported third quarter 2026 Revenue of USD 17.23 million, against an estimate of USD 16.32 million. The loss per share was USD 2.89, compared with an estimate of a USD 2.39 loss. The company discussed its third quarter 2026 financial results and operational highlights on an earnings call.
Net loss for the quarter was USD 53.3 million, an increase of USD 21.3 million, or 66.6%, compared with a net loss of USD 32.0 million in the third quarter of 2025. The company's chief executive officer, Dr. Seth Lederman, joined the call alongside other members of management.
Operating Expenses and Contract Income
Research and development expenses were USD 25.8 million, an increase of USD 16.5 million, or 178%, from USD 9.3 million in the third quarter of 2025. Selling, general and administrative expenses were USD 45.6 million, an increase of USD 19.9 million, or 77%, from USD 25.7 million.
Contract income under the company's DTRA contract was USD 0.7 million, a decrease of USD 0.3 million, or 30%, from USD 1.0 million in the prior-year quarter. The filing presents these figures in the management discussion of results for the three months ended September 30, 2026.
TONMYA and Clinical Programs
The filing describes TONMYA, a cyclobenzaprine HCl sublingual tablet at 2.8 mg, as the company's flagship internally developed medicine and the first new medicine for fibromyalgia in adults approved by the FDA. The company received FDA approval for TONMYA for the treatment of fibromyalgia in adults in August 2025 and commercially launched it in November 2025.
The company is also exploring TNX-102 SL in Phase 2 Clinical Trials for major depressive disorder and for acute stress disorder and acute stress reaction. A potentially pivotal Phase 2 study of TNX-102 SL as a first-line monotherapy in adults with major depressive disorder, called the HORIZON study, commenced in June 2026 and is currently enrolling.
Liquidity and Going Concern
The company held cash and cash equivalents of approximately USD 162.8 million as of September 30, 2026. The filing states that certain factors raise substantial doubt about the company's ability to continue as a going concern.
The call opened with a statement referring to risks described in the company's Annual Report on Form 10-K for the year ended December 31, 2025 and its subsequent quarterly reports on Form 10-Q. It was introduced by its head of Investor relations and included remarks from its chief commercial officer and chief financial officer, who covered commercial progress and the financial results for the quarter.
Tonix Pharmaceuticals Q3 2026 Earnings: Key Takeaways
Tonix Pharmaceuticals reported third quarter 2026 revenue of USD 17.23 million and a loss per share of USD 2.89. Net loss was USD 53.3 million, Research and Development expenses were USD 25.8 million, and cash and cash equivalents were approximately USD 162.8 million.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...